Učitavanje...
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation
AIMS: Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective ‘extended RAS’ analyses have been performed on clinical trial material. Despite this, are...
Spremljeno u:
| Izdano u: | J Clin Pathol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5256378/ https://ncbi.nlm.nih.gov/pubmed/27681846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jclinpath-2016-203822 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|